Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Hjerte-CT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Caffeine and myocardial perfusion: a clinical perspective

    Publikation: Bidrag til tidsskriftLederpeer review

  4. The Authors' Reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  • Christina Byrne
  • Manan Pareek
  • Muthiah Vaduganathan
  • Tor Biering-Sørensen
  • Arman Qamar
  • Ambarish Pandey
  • Thomas Bastholm Olesen
  • Michael Hecht Olsen
  • Deepak L Bhatt
Vis graf over relationer

AIMS: The 2018 ESC/ESH guidelines for hypertension recommend differential management of patients who are <65, 65-79, and ≥80 years of age. However, it is unclear whether intensive blood pressure lowering is well-tolerated and modifies risk uniformly across the age spectrum.

METHODS AND RESULTS: SPRINT randomized 9361 high-risk adults without diabetes and age ≥50 years with systolic blood pressure 130-180 mmHg to either intensive or standard antihypertensive treatment. The primary efficacy endpoint was the composite of acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. The primary safety endpoint was composite serious adverse events. We assessed whether age modified the efficacy and safety of intensive vs. standard blood pressure lowering using Cox proportional-hazards regression and restricted cubic splines. In all, 3805 (41%), 4390 (47%), and 1166 (12%) were <65, 65-79, and ≥80 years. Mean age was similar between the two study groups (intensive group 67.9 ± 9.4 years vs. standard group 67.9 ± 9.5 years; P = 0.94). Median follow-up was 3.3 years. In multivariable models, age was linearly associated with the risk of stroke (P < 0.001) and non-linearly associated with the risk of primary efficacy events, death from cardiovascular causes, death from any cause, heart failure, and serious adverse events (P < 0.001). The safety and efficacy of intensive blood pressure lowering were not modified by age, whether tested continuously or categorically (P > 0.05).

CONCLUSION: In SPRINT, the benefits and risks of intensive blood pressure lowering did not differ according to the age categories proposed by the ESC/ESH guidelines for hypertension.

TRIAL REGISTRATION: SPRINT (Systolic Blood Pressure Intervention Trial); Identifier: NCT01206062,

TidsskriftEuropean heart journal. Cardiovascular pharmacotherapy
Udgave nummer6
Sider (fra-til)356-363
Antal sider8
StatusUdgivet - 1 nov. 2020

ID: 57982595